Serhat Gumrukcu faces trial in a purported plot to kill an associate who could have exposed him and derailed a drug-development deal worth millions. From a report: Even as a teenager back in Turkey, Serhat Gumrukcu dazzled audiences. In a 2002 video, he opened one of his magic shows dancing with a cane that appeared to be levitating. He was introduced as a medical student and went by the stage name "Dr. No." A little more than a decade later, not long after Mr. Gumrukcu arrived in the U.S., he had his hand in multimillion-dollar oil and real-estate deals. Yet his best-known venture was in medicine. For a time, he thrilled investors with ideas for groundbreaking treatments and drew special notice from the government's top infectious-disease official, Anthony Fauci. In America, the magician had found a new, more lucrative audience.

Enochian Biosciences co-founded by Mr. Gumrukcu in 2018, paid more than $21 million to companies controlled by Mr. Gumrukcu and his husband for consulting, research and the licensing of potential drugs to treat influenza, hepatitis B, HIV and Covid-19, company financial filings show. "Dr. Gumrukcu is one of those rare geniuses that is not bound by scientific discipline or dogma. He sees connections and opportunities often missed," Enochian Vice Chairman Mark Dybul, now chief executive, said in a 2019 news release about Enochian's licensing of a hepatitis B drug from a company controlled by Mr. Gumrukcu. Mr. Gumrukcu's success as a biotech entrepreneur afforded the purchase last year of an $18.4 million office complex in North Hollywood, a neighborhood in Los Angeles, and, earlier, a $5.5 million house in the Hollywood Hills.

Yet much of what people saw in Mr. Gumrukcu was an illusion he cast, misrepresenting himself and his credentials, according to state and federal authorities, court records, former colleagues and those who have sued and won judgments against him over fraudulent medical and financial dealings. Prosecutors now allege that Mr. Gumrukcu arranged the murder of a business associate, Gregory Davis, who threatened to expose him as a fraud. Such a revelation would have put at risk the 39-year-old entrepreneur's deal with Enochian, they said. Mr. Gumrukcu has been in custody at the Metropolitan Detention Center in Los Angeles since his arrest on May 24. A federal grand jury indicted him on murder conspiracy charges, an offense punishable by death.

"Researchers at Tsinghua University in China have developed a new drug cocktail that can convert cells into totipotent stem cells, the very seeds of life..." writes New Atlas: Not all stem cells are created equal — they sit in a branching hierarchy of differentiation potential. Multipotent stem cells are found in many tissues in adults, where they can turn into a few types of cells associated with that tissue or organ to help healing. A step earlier in the development tree are pluripotent stem cells, which are found in embryos and can become almost any type of cell in the body.

But at the top of the chain sit what are known as totipotent stem cells, which can become any cell in the body as well as supportive tissues like the placenta. These mark the very beginning of development, including the first single cell that forms from a fertilized egg, and they persist for the first few stages of development. After that, the cells differentiate into pluripotent stem cells and further specialize into all the cells of the body as it develops.

In recent years scientists have been able to take adult cells and induce a pluripotent state in them, which forms the basis of research into stem cell regenerative medicine. But in the new study, the Tsinghua team took things a step further, returning pluripotent stem cells to a totipotent state for the first time...

This breakthrough could open up some major new opportunities, the team says. In the long run, scientists could potentially create a living organism straight from a mature cell, sidestepping the need for sperm and eggs. That could help people have children who otherwise couldn't, or aid conservation of endangered species.

The researchers do acknowledge, however, that ethical concerns will no doubt arise.
Thanks to long-time Slashdot reader hackingbear for sharing the news.

An anonymous reader quotes a report from the Guardian: More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey. Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll found that 53% of people support the use of human genome editing to prevent children from developing serious conditions such as cystic fibrosis.

There was less enthusiasm for use of the procedure to prevent milder conditions such as asthma, with only 36% in favor, and to create designer babies, with only a fifth expressing support, but views on the technology differed dramatically with age. Younger generations were far more in favor of designer babies than older people, with 38% of 16- to 24-year-olds and 31% of 25- to 34-year-olds supporting the use of gene editing to allow parents to choose features such as their child's height and eye and hair color. In the UK and many other countries it is illegal to perform genome editing on embryos that are intended for pregnancies, but the restrictions could be lifted if research shows the procedure can safely prevent severe diseases.

The Guardian reports: Scientists have successfully developed a revolutionary cancer treatment that lights up and wipes out microscopic cancer cells, in a breakthrough that could enable surgeons to more effectively target and destroy the disease in patients.

A European team of engineers, physicists, neurosurgeons, biologists and immunologists from the UK, Poland and Sweden joined forces to design the new form of photoimmunotherapy. Experts believe it is destined to become the world's fifth major cancer treatment after surgery, chemotherapy, radiotherapy and immunotherapy. The light-activated therapy forces cancer cells to glow in the dark, helping surgeons remove more of the tumours compared with existing techniques — and then kills off remaining cells within minutes once the surgery is complete. In a world-first trial in mice with glioblastoma, one of the most common and aggressive types of brain cancer, scans revealed the novel treatment lit up even the tiniest cancer cells to help surgeons remove them — and then wiped out those left over. Trials of the new form of photoimmunotherapy, led by the Institute of Cancer Research, London, also showed the treatment triggered an immune response that could prime the immune system to target cancer cells in future, suggesting it could prevent glioblastoma coming back after surgery....

The therapy combines a special fluorescent dye with a cancer-targeting compound. In the trial in mice, the combination was shown to dramatically improve the visibility of cancer cells during surgery and, when later activated by near-infrared light, to trigger an anti-tumour effect.

In 2003, the Human Genome Project finished sequencing every bit of human DNA, remembers MIT News.

"Now, over two decades later, MIT Professor Jonathan Weissman and colleagues have gone beyond the sequence to present the first comprehensive functional map of genes that are expressed in human cells." The data from this project, published online June 9 in Cell, ties each gene to its job in the cell, and is the culmination of years of collaboration on the single-cell sequencing method Perturb-seq.

The data are available for other scientists to use. "It's a big resource in the way the human genome is a big resource, in that you can go in and do discovery-based research," says Weissman, who is also a member of the Whitehead Institute and an investigator with the Howard Hughes Medical Institute....

"I think this dataset is going to enable all sorts of analyses that we haven't even thought up yet by people who come from other parts of biology, and suddenly they just have this available to draw on," says former Weissman Lab postdoc Tom Norman, a co-senior author of the paper.
The announcement credits the single-sequencing tool Perturb-seq and CRISPR-Cas9 genome editing which introduced genetic changes into cells and then captured information about which RNAs expressed (uses single-cell RNA sequencing).

The researchers scaled the method to the entire genome using human blood cancer cell lines and noncancerous cells derived from the retina, ultimately using Perturb-seq across more than 2.5 million cells.

Thanks to Slashdot reader Hmmmmmm for sharing the news.

"In molecular biologist David Sinclair's lab at Harvard Medical School, old mice are growing young again," reports CNN: Using proteins that can turn an adult cell into a stem cell, Sinclair and his team have reset aging cells in mice to earlier versions of themselves. In his team's first breakthrough, published in late 2020, old mice with poor eyesight and damaged retinas could suddenly see again, with vision that at times rivaled their offspring's.

"It's a permanent reset, as far as we can tell, and we think it may be a universal process that could be applied across the body to reset our age," said Sinclair, who has spent the last 20 years studying ways to reverse the ravages of time.

"If we reverse aging, these diseases should not happen. We have the technology today to be able to go into your hundreds without worrying about getting cancer in your 70s, heart disease in your 80s and Alzheimer's in your 90s." Sinclair told an audience at Life Itself, a health and wellness event presented in partnership with CNN.

"This is the world that is coming. It's literally a question of when and for most of us, it's going to happen in our lifetimes," Sinclair told the audience.... Sinclair said his lab has reversed aging in the muscles and brains of mice and is now working on rejuvenating a mouse's entire body.
The article points out that he's building on research by Japan's Dr. Shinya Yamanaka (which in 2007 won a Nobel prize).

But one key caveat: "Studies on whether the genetic intervention that revitalized mice will do the same for people are in early stages, Sinclair said. It will be years before human trials are finished, analyzed and, if safe and successful, scaled to the mass needed for a federal stamp of approval."

Humble Bee Bio is on a mission to create a biodegradable alternative to plastics by synthesizing the biology of bees. TechCrunch reports: While the New Zealand-based company is still at an early stage -- it's about halfway through its proof of concept -- if Humble Bee is successful, its bioplastics are likely to make it into the sustainable textiles industry. Humble Bee, which just raised $3.2 million (NZD $5 million) in convertible notes as part of its Series A, has been studying the Australian masked bee, a type of solitary bee that doesn't make honey, but does make a nesting material for laying larvae in, which has many plastic-like properties. "It's resistant to acids and bases. It's hydrophobic, it's waterproof, it's flame retardant, it's stable up to 240 degrees Celsius," Ryan Graves, Humble Bee's chief technology officer, told TechCrunch. "The idea is, how do we recreate this?"

The team is using a synthetic biology approach that involves going into the bee's genetic code and identifying the genes and proteins responsible for the nesting material. Humble Bee has extracted the code and is trying to recreate it in the laboratory. Next, the company will attempt to synthesize plastic-like materials, focusing on four different types of biomaterials that can be turned into fibers and finishing for fabrics. Humble Bee is aiming for anywhere from March to June 2023 to prove out the concept, at which point the team hopes to scale production using industrial-scale fermentation. "There's a degree of exploration still to go on," said Graves, "The processes are time-intensive and they are challenging. Getting going from code to protein is usually a 12-month process, and then we need to scale it up to get hundreds of grams of the stuff out."

An anonymous reader quotes a report from The Guardian: The building of the world's largest bioreactors to produce cultivated meat has been announced, with the potential to supply tens of thousands of shops and restaurants. Experts said the move could be a "gamechanger" for the nascent industry. The US company Good Meat said the bioreactors would grow more than 13,000 tons of chicken and beef a year. It will use cells taken from cell banks or eggs, so the meat will not require the slaughter of any livestock. There are about 170 companies around the world working on cultured meat, but Good Meat is the only company to have gained regulatory approval to sell its product to the public. It began serving cultivated chicken in Singapore in December 2020.

The creation of Good Meat's 10 new bioreactors is under way, the company says, each of which has a capacity of 250,000 liters and will stand four stories tall, far bigger than any constructed to date. The US site for the facility is due to be finalized within three months and operational in late 2024, reaching 11,800 tons a year by 2026 and 13,700 tons by 2030. The bioreactors are being manufactured as part of an agreement with ABEC, a leading bioprocess equipment manufacturer, which is also making a 6,000-liter bioreactor for Good Meat's Singapore site -- this is scheduled to begin production in early 2023 and will itself be the biggest cultured meat bioreactor installed to date. Cultivated meat has not yet been approved for sale by the US Food and Drug Administration. "Weâ(TM)ve submitted our application," said Josh Tetrick, the chief executive of Good Meatâ(TM)s parent company, Eat Just. "Weâ(TM)ve found the agency to be fully engaged, asking all the questions youâ(TM)d expect, from cell identification to final product. Weâ(TM)d prefer not to try to predict if and when [approval] will occur."

Tetrick also said the company had produced a cell growth serum that does not require the use of bovine fetuses, which were previously widely used.

An anonymous reader quotes a report from The Guardian: Scientists have created genetically edited tomatoes, each containing as much provitamin D3 -- the precursor to vitamin D -- as two eggs or a tablespoon of tuna. Outdoor field trials of the tomatoes are expected to begin in the UK next month, and if successful, could provide an important new dietary source of vitamin D. The tomato plants were created by making tiny changes to an existing tomato gene using an editing technique called Crispr-Cas9. "It's like a pair of molecular tweezers, which you can use to precisely snip out a very small fragment of the gene to enhance a desirable trait in plants a lot quicker than traditional breeding process, and without introducing any foreign DNA from other species," said Jie Li at the John Innes Centre in Norwich, who led the research.

In this case, their focus was an enzyme found in tomato plants that normally converts provitamin D3 into cholesterol. By altering this enzyme, the researchers managed to block this pathway, meaning provitamin D3 accumulated in the tomatoes' fruits and leaves. They calculated that the amount of provitamin D3 in one tomato fruit -- if converted to vitamin D3 -- would be equivalent to levels present in two medium-sized eggs or 28 grams of tuna. To convert this into active vitamin D3, the fruit would still need to be exposed to UVB light, or they could potentially be grown outdoors, something the researchers plan to test in upcoming field trials. The research was published in Nature Plants. "Unlike GMOs, the tomato plants do not contain genes from other organisms and could theoretically have been created through selective breeding -- albeit much more slowly," notes the Guardian. Therefore, they could be allowed under a proposed genetic technology (precision breeding) bill aimed to allow gene-edited plants to be treated differently to genetically modified organisms (GMOs).

The BBC reports on "the next generation of genetic modification technology" — which goes beyond simply introducing a "lab-tweaked gene" into an organism. Instead it introduces a "gene drive" — a lab-tweaked gene "that targets and removes a specific natural gene." if an animal (parent A) that contains a gene drive mates with one that doesn't (parent B), then in the forming embryo that starts to combine their genetic material, parent A's gene drive immediately gets to work. It recognises the natural gene version of itself in the opposite chromosome from parent B, and destroys it, by cutting it out of the DNA chain. Parent B's chromosome then repairs itself — but does so, by copying parent A's gene drive. So, the embryo, and the resulting offspring, are all but guaranteed to have the gene drive, rather than a 50% chance with standard GM — because an embryo takes half its genes from each parent.

Gene drives are created by adding something called Crispr, a programmable DNA sequence, to a gene. This tells it to target the natural version of itself in the DNA of the other parent in the new embryo. The gene drive also contains an enzyme that does the actual cutting.

It is hoped that gene drives can be used to greatly reduce the numbers of malarial mosquitos, and other pests or invasive species.... One organisation at the forefront of this is Target Malaria, which has developed gene drives that stop mosquitos from producing female offspring. This is important for two reasons — only the females bite, and without females, mosquito numbers will plummet. The core aim is to greatly reduce the number of people who die from malaria — of which there were sadly 627,000 in 2020, according to the World Health Organization. It could also slash the economic impact of the disease. With 241 million cases in 2020, mostly in Africa, malaria is estimated to cost the continent $12bn (£9.7bn) in reduced economic output every year....

One of the world's pioneering developers of gene drives is US biologist Kevin Esvelt, an assistant professor at Massachusetts Institute of Technology. He first came up with the technology back in 2013.... Prof Esvelt adds that this technology is being provided by something called "daisy chain". This is where a gene drive is designed to become inert after a few generations. Or halving its spread every generation until it eventually stops. Using this technology he says it is possible to control and isolate the spread of gene drives. "A town could release GM organisms with its boundaries to alter the local population [of a particular organism] while minimally affecting the town next door," he says.
The technology has not been authorized for use "in the wild," the article points out. But there are currently no bans on laboratories researching it.

Bill Gates shares a statistic about the COVID-19 pandemic. "If we'd been able to stop it within 100 days, we would've saved over 98% of the lives." "Viruses spread exponentially, and so if you get in there when the infection rate is fairly small, you can actually stop the spread."
In a new TED talk, Gates argues that we did learn a lot from this pandemic — enough to build a prevention system for next time. "Covid 19 can be the last pandemic if we take the right steps." But the answer isn't vaccines. "We also need vaccines, but we want to stop the outbreak before we have to do a global vaccination campaign." And then Gates points out that currently it could take months to get resources to a low-income country experiencing an outbreak.

Read on for Slashdot's report on Gates' proposed solution — and how he feels about his own prominence in anti-vaccine misinformation.

The Covid-19 pandemic "would look very different if scientists had been able to develop a treatment sooner," writes Bill Gates, in a guest essay Friday in the New York Times. This ultimately would've reduced fatalities — "and it may have been harder for myths and misinformation to spread the way they did."

But note that Gates said "treatment" — not vaccine. Gates believes most people in the public health community had expected an effective treatment would appear before vaccines became available. Unfortunately, that's not what happened. Safe, effective Covid vaccines were available within a year — a historic feat — but treatments that could keep large numbers of people out of the hospital were surprisingly slow out of the gate....

In late 2021, a few of their efforts paid off — not as soon as would have been ideal, but still in time to have a big impact. Merck and its partners developed an antiviral called molnupiravir, which was shown to significantly reduce the risk of hospitalization or death for people at high risk. Soon after, another oral antiviral, Paxlovid, made by Pfizer, also proved to be very effective, reducing the risk of severe illness or death by nearly 90 percent among high-risk, unvaccinated adults. These drugs are useful tools for combating the pandemic, but they arrived much later than they should have and, for many, they are still difficult to access....

It's a mistake to think of vaccines as the star of the show and therapeutics as the opening act you would just as soon skip. We're lucky that scientists made Covid vaccines as quickly as they did — if they hadn't, the death toll would be far worse. But in the event of another pandemic, even if the world is able to develop a vaccine for a new pathogen in 100 days, it will still take a long time to get the vaccine to most of the population.... With good therapeutics, the risk of severe illness and death could drop significantly, and countries could decide to loosen restrictions on schools and businesses, reducing the disruption to education and the economy. What's more, imagine how people's lives would change if we're able to take the next step by linking testing and treatment. Anyone with early symptoms that might indicate Covid (or any other viral disease) could walk into a pharmacy or clinic anywhere in the world, get tested and, if positive for the virus, walk out with antivirals to take at home....

In short, although therapeutics didn't rescue us from Covid, they hold a lot of promise for saving lives and preventing future outbreaks from crippling health systems. But to make the most of that promise, the world needs to invest in the research and systems we'll need to find treatments much faster. That's why my foundation has supported a therapeutics accelerator at Duke University, but broader initiatives will be necessary to make lasting change. This will require substantial investment to bring together academia, industry and the latest software tools. But if we succeed, the next time the world faces an outbreak, we'll save millions more lives.
Gates offers several specific recommendations — including "investing in large libraries of drug compounds that researchers can quickly scan to see whether existing therapies work against new pathogens." And... With advances in artificial intelligence and machine learning, it's now possible to use computers to identify weak spots on pathogens that we already know about, and we'll be able to do the same when new pathogens arise. These technologies are also speeding up the search for new compounds that will attack those weak spots. With adequate funding, various groups could take the most promising new compounds through Phase 1 studies even before there's an epidemic, or at least have several leads that can be turned into a product quickly once we know what the target looks like.

The U.S. government recently gave California approval to release millions of genetically engineered mosquitoes bred by British biotech company Oxitec, reports the Los Angeles Times: Oxitec, a private company, says its genetically modified bugs could help save half the world's population from the invasive Aedes aegypti mosquito, which can spread diseases such as yellow fever, chikungunya and dengue to humans. Female offspring produced by these modified insects will die, according to Oxitec's plan, causing the population to collapse. "Precise. Environmentally sustainable. Non-toxic," the company says on its website of its product trademarked as the "Friendly" mosquito.

Scientists independent from the company and critical of the proposal say not so fast. They say unleashing the experimental creatures into nature has risks that haven't yet been fully studied, including possible harm to other species or unexpectedly making the local mosquito population harder to control....

Nathan Rose, Oxitec's head of regulatory affairs, noted that the company found its mosquito reduced the population in a Brazilian neighborhood by 95% in just 13 weeks. So far, Oxitec has released little of its data from that experiment or from a more recent release in the Florida Keys. It hasn't yet published any of those results in a peer-reviewed scientific journal — publications that scientists expect when evaluating a new drug or technology....

Among scientists' concerns is that releasing the genetically modified mosquitoes into neighborhoods could create hybrids that are hardier and more dangerous to humans than the state's current population.... An EPA spokesperson said regulators expected that mosquitoes with the corporate genes "would disappear from the environment within 10 generations of mosquitoes because they are not able to reproduce as successfully as local populations." To prove this, the agency has required Oxitec to monitor neighborhoods for mosquitoes that have DNA from its engineered insects until none have been found for at least 10 consecutive weeks.
One bioethicist at Harvard Medical School told the Times that California has never had a case where this breed of mosquitos had actually transmitted disease, and argued that America's Environmental Protection Agency was "not a modern enough regulatory structure for a very modern and complicated technology."

After the U.S. government's approval, the genetically-engineered mosquitors still face several more months of scientific evaluation from California's Department of Pesticide Regulation.

Thanks to long-time Slashdot reader schwit1 for sharing the link

An anonymous reader quotes a report from the Guardian: Scientists have developed a blood test that can predict whether someone is at high risk of a heart attack, stroke, heart failure or dying from one of these conditions within the next four years. The test, which relies of measurements of proteins in the blood, has roughly twice the accuracy of existing risk scores. It could enable doctors to determine whether patients' existing medications are working or whether they need additional drugs to reduce their risk. It could also be used to hasten the development of new cardiovascular drugs by providing a faster means of assessing whether drug candidates are working during clinical trials. The test is already being used in four healthcare systems within the US and [...] it could be introduced to the UK in the near future.

[Researchers] used machine learning to analyze 5,000 proteins in blood plasma samples from 22,849 people and identify a signature of 27 proteins that could predict the four-year likelihood of heart attack, stroke, heart failure or death. When validated in 11,609 individuals, they found their model was roughly twice as good as existing risk scores, which use a person's age, sex, race, medical history, cholesterol and blood pressure to assess their likelihood of having a cardiovascular event. The results were published in Science Translational Medicine. Importantly, the test can also accurately assess risk in people who have previously had a heart attack or stroke, or have additional illnesses, and are taking drugs to reduce their risk, which is where existing risk prediction scores tend to fall down.

"Researchers in the United Kingdom have developed an autonomous, snakelike robot designed to slither down human lungs into places that are difficult for medical professionals to reach," reports the Washington Post.

The tool "could improve the detection and treatment of lung cancer and other pulmonary diseases." In a medical paper released in the journal of Soft Robotics last week, scientists from the University of Leeds unveiled a new "magnetic tentacle robot," which is composed of magnetic discs and is roughly 2 millimeters thick — about double the size of a ballpoint pen tip — and less than a-tenth-of-an-inch long.

In the future, the robot's use could be expanded to help doctors better, and more thoroughly, investigate other organs, such as the human heart, kidney or pancreas, they said....

The robot is still 5 to 10 years away from showing up in a clinical setting, researchers said, but the device comes on the heels of a fleet of other robotic innovations allowing doctors the ability to better scan a patient's lungs for cancerous tissue. They are designed to ease a task doctors have long struggled with: reaching the inner recesses of the human body, for diagnostic and treatment purposes, without causing damage or using invasive procedures.... [I]ts smaller size and magnetic composition would allow it to shape-shift more easily and better navigate the intricate shape of a lung's network of airways, which can look like a tree....

Once at its desired location, the robot could ultimately have the capability to take a tissue sample or deliver a clinical treatment.... Nitish V. Thakor, a professor of biomedical engineering at Johns Hopkins University, said the autonomous robot is "very novel and interesting technology" that could become potentially useful in areas outside the lungs, most notably the heart. The device's autonomous capability is its unique factor, he said, and has the capability to change invasive surgeries. "I can imagine a future," he said, "where a full [cancer-screening] CAT scan is done of the lungs, and the surgeon sits down on a computer and lays out this navigation path of this kind of a snake robot and says: 'Go get it.' "

An anonymous reader quotes a report from New Atlas: One of the first products made using a novel animal-free egg white is now available in the United States. The unique macarons are the first to be made with an egg white protein that comes from engineered yeast, designed to be indistinguishable from what is found in chicken eggs. The Every Company, founded in 2014 under the name Clara Foods, is one of several food technology companies working to create real animal-free proteins using a method called precision fermentation. The idea behind the process is to break down certain animal products, such as milk and eggs, to their molecular components and then use microorganisms to produce those components. Earlier this year the first cow-free dairy milk using this method hit supermarket shelves in the United States. That product was created using whey proteins from engineered fungus, while other companies are working on similar dairy products using engineered yeast to produce the desired milk proteins.

The Every Company has spent the last few years focusing on using the same technique to produce chicken-free egg whites, working with engineered yeast to produce proteins found in egg whites. The company has not disclosed the specific combination of proteins used to create its final egg white product, however it is likely ovalbumin -- the primary protein component in egg whites -- plays a strong role in the recipe. Arturo Elizondo, CEO of Every Company, said the new egg white product functions exactly like a chicken-derived egg white. It whips, aerates and bakes in ways identical to traditional egg whites, and the company has teamed up with San Francisco-based bakery Chantal Guillon to launch the product in a line of iconic French macarons. The chicken-free egg white is the third animal-free product created by the Every Company. Its first fully commercialized product was an animal-free pepsin, launched in early 2021.

On Saturday CNBC published a remarkable headline. "Stem cells may finally offer a cure for Type 1 diabetes." There are 537 million people around the world living with diabetes. And that number is growing.... But over the past 20 years, significant advancements in stem cell research and therapies have revealed promising methods of creating new insulin-making cells, which are needed to cure Type 1 diabetes. Biotech company Vertex Pharmaceuticals recently began a clinical trial where it plans to treat 17 participants who have Type 1 diabetes with new insulin-making cells derived from stem cells. The first patient in the trial, Brian Shelton, has had positive results. After 150 days, Shelton was able to reduce the amount of insulin he injects by 92%.

Other global companies are also working to cure diabetes, such as ViaCyte, CRISPR, and Novo Nordisk, one of the biggest insulin manufacturers in the world.
In CNBC's 20-minute video, a VP/disease area executive from Vertex Pharmaceuticals explains that diabetes is "one of the few diseases where a single cell type is destroyed or missing" — the pancreas cell that produces insulin. So they're exploring "the idea that if you could create those cells and replace them, you can really address the underlying causal biology of the disease directly."

CNBC also spoke to Brian Shelton, the trial's first patient, who's been a Type 1 diabetic for 44 years, and whose pancreas suddenly started producing insulin again. "Now my body does it all on its own," Shelton says. The news was especially surprising, CNBC reports, because "as the first person in the trial, Shelton received only half of the anticipated dose to ensure it was safe."

One researcher they spoke to even predicts that biological solutions will compete with "ongoing efforts to use nanotechnology to miniaturize all the hardware necessary to do this," and that within the next 3 to 5 years patients will finally have the option of "something that is really Cadillac." And Aaron Kowalski, CEO of the nonprofit Juvenile Diabetes Research Foundation, tells CNBC, "I am fully convinced that I will walk away from my insulin pump and continuous glucose monitor in my lifetime, and I would be disappointed if it wasn't in this decade."

CNBC's report concludes, "For diabetics who want a cure that requires no additional treatment, it may no longer be a question of if, but a matter of when."

The U.S. government's "dithering" has left the country "well behind" China in the race to build out 5G technology, former Google CEO Eric Schmidt said, as he urged Washington to step up investment in the next-generation internet technology. From a report: Writing in an op-ed in the Wall Street Journal, Schmidt and Graham Allison, a professor of government at Harvard, said that America is "far behind in almost every dimension of 5G while other nations -- including China -- race ahead." The authors urged the Biden administration to make 5G a "national priority." Otherwise, they said, "China will own the 5G future." 5G refers to next-generation wireless internet that promises super-fast download speeds. But it could also form the basis for industrial and military applications and form a way for devices to communicate with each other. That's why it's seen as a critical technology and one of the reasons China is moving quickly with its own 5G rollout and future applications.

New submitter blackprint writes: The City of Austin released a memo saying that Samsung released as much as 763,000 gallons of sulfuric acid waste into a Northeast Austin creek over a period as long as 106 days. They confirmed the leak has stopped, but no fish or macro invertebrates survived in the impacted area. They don't know if there are any long-term impacts, but pH levels in the area have returned close to normal. According to the memo, "Public access to this area is limited, and there are no nearby parks."

They have not stated the cause of the spill. "Spill investigators and scientists took a look at the area Jan. 18-19 and saw iron staining in the tributary channel consistent with a low pH environment," reports local news station KXAN, citing the memo. "WPD says it was in this tributary stretch from the Samsung plant to the main branch of Harris Branch Creek that WPD staff found no surviving aquatic life, including fish."

An anonymous reader quotes a report from Motherboard: Dr. Garry Nolan is a Professor of Pathology at Stanford University. His research ranges from cancer to systems immunology. Dr. Nolan has also spent the last ten years working with a number of individuals analyzing materials from alleged Unidentified Aerial Phenomenon. His robust resume -- 300 research articles, 40 US patents, founding of eight biotech companies, and honored as one of Stanford's top 25 inventors -- makes him, easily, one of the most accomplished scientists publicly studying UAPs. Motherboard sat down with Garry to discuss his work. It has been edited for length and clarity. Motherboard's Thobey Campion starts by asking Dr. Nolan how he first became interested in UAPs. I've always been an avid reader of science fiction, so it was natural at some point that when YouTube videos about UFOs began to make the rounds I might watch a few. I noticed that this guy at the time, Steven Greer, had claimed that a little skeleton might be an alien. I remember thinking, 'Oh, I can prove or disprove that.' And so I reached out to him. I eventually showed that it wasn't an alien, it was human. We explain a fair amount about why it looked the way it did. It had a number of mutations in skeletal genes that could potentially explain the biology. The UFO community didn't like me saying that. But you know, the truth is in the science. So, I had no problem just stating the facts. We published a paper and it ended up going worldwide. It was on the front page of just about every major newspaper. What's more appealing or clickbait than 'Stanford professor sequences alien baby'?

That ended up bringing me to the attention of some people associated with the CIA and some aeronautics corporations. At the time, they had been investigating a number of cases of pilots who'd gotten close to supposed UAPs and the fields generated by them, as was claimed by the people who showed up at my office unannounced one day. There was enough drama around the Atacama skeleton that I had basically decided to forswear all continued involvement in this area. Then these guys showed up and said, 'We need you to help us with this because we want to do blood analysis and everybody says that you've got the best blood analysis instrumentation on the planet.' Then they started showing the MRIs of some of these pilots and ground personnel and intelligence agents who had been damaged. The MRIs were clear. You didn't even have to be an MD to see that there was a problem. Some of their brains were horribly, horribly damaged. And so that's what kind of got me involved. Dr. Nolan expanded on the MRIs, saying they resemble the white matter disease, or scarring, that occurs with multiple sclerosis, with the symptomology that's basically identical to what's now called Havana syndrome. "That still left individuals who had seen UAPs. They didn't have Havana syndrome. They had a smorgasbord of other symptoms."

When asked if there's anything man-made that might have this impact on the brain, Dr. Nolan said: "The only thing I can imagine is you're standing next to an electric transformer that's emitting so much energy that you're basically getting burned inside your body."

As for the UAP fragments, Dr. Nolan said some of the objects are "nondescript," and just "lumps of metal" with nothing particularly unusual about them "except that everywhere you look in the metal, the composition is different, which is odd." He added: "The common thing about all the materials that I've looked at so far, and there's about a dozen, is that almost none of them are uniform. They're all these hodgepodge mixtures. Each individual case will be composed of a similar set of elements, but they will be inhomogeneous."

Of the 10 or 12 UAP fragments he's looked at, "two seem to be not playing by our rules," he says. "That doesn't mean that they're levitating, on my desk or anything, it just means that they have altered isotope ratios."

You can read the full Q&A here.